Genomma Lab Internacional SAB de CV Class B · BMV:LAB/B
Genomma Lab Internacional SAB de CV Class B — Investor Presentation (May 2024)
100 slides from Genomma Lab Internacional SAB de CV Class B's investor presentation, May 2024
Slide 1: Genomma Lab Internacional
Genomma Lab.°® Internacional
Slide 2: Investor Relations Corporate Presentation
INVESTOR RELATIONS CORPORATE PRESENTATION
Slide 3: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements
Slide 4: Content
1 Who We Are: Our Footprint 2 5-year Profit & Growth Strategy Content 3 Unleashing Shareholder Value 4 Financial Review April 2024 4
Slide 5: New High-Growth Strategy
* New High-Growth Strategy • “The ideal Partner for • Leading Latin America and the Pharmaceutical U.S. Hispanic Market” and Personal • Europe : United Pharmaceuticals Care Company • U.S. : Edgewell • Japan : Rohto • Israel : Oramed • Assessing selected high-ROIC • Consistent base growth potential p
Slide 6: Footprint: Latin America
Footprint : Latin America CHALLENGES OPPORTUNITIES • General economy • Population + 663 million (2x USA) stagnation • GDP per capita 0.2 x USA • Political inestability • Total GDP = 0.4x USA • Employment & • Median Age : 31 years Livelihood crisis MAPA • Inequality translates into • Increment in ill
Slide 7: Genomma Lab Internacional: Base Business
Genomma Lab Internacional : Base Business • Genomma develops, manufactures and markets a broad range of premium branded products, many of which are leaders in their categories SEGMENT MEGA-BRANDS GEOGRAPHY US OTC 10% Mexico 52% LatAm 48% 42% 48% PC + Beverages April 2024 7
Slide 8: Over The Counter Products: 52% of Total Sales
Over The Counter Products (OTC): 52% Of Total Sales* Pain Relief Cough & Cold Gastro & Anti- Hemorrhoids Anti-mycotics & Anti-Flu Sexual Health April 2024 8
Slide 9: Personal Care Products + Beverages: 48% of Total Sales
Personal Care Products (PC) + Beverages: 48% Of Total Sales* Specialized Hair Care Skin Care Beauty Care Isotonic beverages Shampoo Anti-Acne & Cosmetics 9
Slide 10: New Categories
New Categories: Antibacterial Male Care & Grooming Infant Nutrition April 2024 10
Slide 11: International Business Model
International Business Model US dollar: Guatemala 10% Honduras El Salvador Other currencies: USA Belize Costa Rica INTERNATIONAL 23% 42% Panama Nicaragua 1. Brazilian Real MEXICO 52% 2. 3. Colombian Peso Chilean Peso CARICAM 4. Peruvian Sol 5. Argentine Peso Colombia MEXICO 6. 7. Uruguayan Peso Para
Slide 12: Content
1 Who We Are: Our Footprint 2 5-year Profit & Growth Strategy Content 3 Unleashing Shareholder Value 4 Financial Review April 2024 14
Slide 13: Evolution of Growth Strategy
Evolution of Growth Strategy 4-year trend : consistent Sales and Profit growth Net Sales EBITDA INITIATIVES TO FURTHER CAGR CAGR IMPROVE PROFITABILITY 6.7%* 7.7% • Manufacturing Plant and Supply Chain synergies • AI-based media investment optimization • Cost optimization strategies • Strategic Partn
Slide 14: Growth Strategic Framework 2025
Growth Strategic Framework → 2025 Product Innovation Superior Best-In-Class Brand Value Go-To-Market & e-Commerce Our Sustainability Commitment Strategic World-Class Partnerships & Supply Chain Technology Winning Culture & Organization April 2024 16
Slide 15: Product Innovation
Product Innovation Recycled Royal Jelly Shampoo Healthy Hair, Healthy Planet Eco-friendly Recycled Conscious communication 100% 100% recycled sustainable and recyclable packaging PETE bottle Recycling meeting points High quality ingredients April 2024 17
Slide 16: Product Innovation
Product Innovation Masstige Affordable Luxury Hi-quality Performance April 2024 18
Slide 17: New High (Inorganic) Growth Strategy
New High (Inorganic) Growth Strategy M&A • Current environment : high valuations due to global apetite in OTC and PC brands, and low interest rates PARTNERSHIPS • Innovative products and services High ROIC -> • Extensive R&D capabilities Shareholder • Low capital investments value creation • Leverag
Slide 18: The Ideal Partner for Latin America and the U.S. Hispanic Market
“The ideal Partner for Latin America and the U.S.Hispanic Market” Genomma Lab Internacional April 2024 20
Slide 19: Strategic Alliances
Strategic Alliances New category with growth potential for Mexico & LatAm Manufactured by Edgewell PC (Strategic Partnership) Market Value opportunity of >100mm USD April 2024 21
Slide 20: Strategic Alliances
Strategic Alliances Manufactured by UP International (Strategic Partnership) Exclusivity in Mexico and Latin America ex. Brazil Market Value opportunity of >80mm USD April 2024 22
Slide 21: Exploring expansion to other territories
Exploring expansion to other territories • Developing a franchise business to expand the presence of power brands in other territories, partnering with strong local players overseas • Low cost manufacturing, sustainable products • Full marketing/advertising and Point-of-Sale material • Cicatricure,
Slide 22: Superior Brand Communication
Superior Brand Communication SOCIAL RESPONSIBILITY Click on images to watch the latest product communication April 2024 24
Slide 23: Proprietary Process to Win the Consumer Experience
Always-on Analytics and Precision Marketing Proprietary Process to Win the Consumer Experience Always-on Analytics and Precision Marketing Understanding Online Market Design Experts Effective Research with Across all of Consumers in communication media Choices Thousands of E-Commerce vehicles platfo
Slide 24: The Largest Content Studio in the World of CPGs and Pharma
The largest Content Studio (25 years) in the world of CPGs and Pharma Companies, now including Digital Content • 25 years developing the largest multi-media content in Latin America • > 2.1 PetaBytes of media content (Over 2,140,000,000 GB of photos, videos, animation & digital content produced in-h
Slide 25: Best in Class Go-to-Market
From the Bottom-of-the-Pyramid to the top Best in Cass Go-to-Market Multi- Channel Traditional Channel Superior POS visibility • +308,000 • Modern Trade Points of Sale • Pharma Wholesalers • Pharma Chain • E-Commerce (B2C) • Amazon & other e-Retailers • Direct Sales Distribution (DSD) • Independent
Slide 26: Corporate Culture & Organization
Corporate Culture & Organization Genomma Way Breaking Down Barriers • GenBook, new corporate How are we doing it? philosophy • Upskilling • Competitive Compensation • Career Development • Connected Organization Equal opportunity April 2024 28
Slide 27: 2025 Sustainability Strategy
2025 Sustainability Strategy Click here to read our 2025 Sustainability Strategy +10 Years Being Recognized As One Of The Leading Companies In ESG Practices. April 2024 29
Slide 28: MSCI ESG Rating Upgrade
MSCI ESG Rating Upgrade Improved three notches in a 4 year period April 2024
Slide 29: Capital Allocation, Ratings & Long-term Financing
Capital Allocation, Ratings & Long-term Financing • CASH DIVIDEND • SHARE BUY-BUCKS • OPTIMIZE FINANCIAL LEVERAGE • STRATEGIC PARTNERSHIPS / M&A Short-Term: Short-Term: F1+(mex) HR+1 Long-Term: Long-Term: AA+(mex) HR AA+ Outlook: Outlook: Stable Stable April 2024 31
Slide 30: World-class Manufacturing & Supply Chain
World-class Manufacturing & Supply Chain Enhanced Value Equation Higher Gross Margin US$ 100 MM Superior Product Quality 8 years term Reliable Product Supply loan 1 2 3 April 2024 32
Slide 31: PC Manufacturing Facility Update
PC Manufacturing Facility Update Suerox® Manufacturing Line +8,000,000 bottles produced in June-23 April 2024 33
Slide 32: PC Manufacturing Facility Update: Isotonic Beverage Line
PC Manufacturing Facility Update Isotonic Beverage Line
Slide 33: Central Warehouse, PC and OTC Manufacturing Facility
Central Warehouse, PC and OTC Manufacturing Facility April 2024 35
Slide 34: OTC Manufacturing Facility Update
OTC Manufacturing Facility Update Tube filling equipment for semi- Water chiller system for OTC Plant solid production line Tanks system for liquid OTC production Semi-solid production line State-of-the-art equipment April 2024 36
Slide 35: Content
1 Who We Are: Our Footprint 2 4-year Profit & Growth Strategy Content 3 Unleashing Shareholder Value 4 Financial Review April 2024 37
Slide 36: Genomma Lab Internacional
Genomma Lab Internacional April 2024 38
Slide 37: Genomma Lab Internacional
Genomma Lab Internacional April 2024 39
Slide 38: Brand Portfolio: 45% of Business Growing Share
BRAND PORTAFOLIO 45% OF BUSINESS GROWING SHARE Analgesics Derma OTC Cough & Cold Gastro April 2024
Slide 39: Brand Portfolio: 78% Growing Above Inflation
BRAND PORTAFOLIO 78% OF BUSINESS GROWING ABOVE INFLATION +170% April 2024
Slide 40: Genomma Lab Internacional
Genomma Lab Internacional April 2024 42
Slide 41: Genomma Lab Internacional
Genomma Lab Internacional April 2024 43
Slide 42: Genomma Lab Internacional
Genomma Lab Internacional April 2024 44
Slide 43: Genomma Lab Internacional
Genomma Lab Internacional April 2024 45
Slide 44: Hair Care
Category Size: SOM: 2.6 Bn USD 5% Leads the natural products industry trend 100% sustainably-sourced packaging CAGR +8% (2018-2023) +23% SOM Market Leader Chile 5.1% 11.7% Brazil 4.3% 12.9% Colombia 4.6% 8.3% -2.2% Peru 4.5% 12.0% Argentina 2.7% 10.5% Q1 2024 Mexico 2.6% 9.0% 2018 2019 2020 2021 202
Slide 45: Isotonic Beverages
Category Size: SOM: Isotonic Beverages 1.9 Bn USD 4.6% Leads the world hydration trend 8 ions, no sugar, no calories KEY HIGHLIGHTS: +42% • Robust performance across regions • Suerox launched in +10 markets CAGR +44% (2018-2023) +14% Q1 2024 2018 2019 2020 2021 2022 2023 2024 April 2024
Slide 46: Genomma Lab Internacional
Genomma Lab Internacional April 2024
Slide 47: Country Expansion
SUSey< COUNTRY EXPANSION 2022 COUNTRY FOOTPRINT. 2023 PLAN *RAIA DROGASIL,
Slide 48: Razors & Blades
Providing value to consumers with longer-lasting blades & razors KEY HIGHLIGHTS: • Capturing more market share in both Mexico and Chile • Launch of disposable and cartridge SKUs driving growth in Mexico CAGR +50% (2018-2023) +36% +13% Q1 2024 2020 2021 2022 2023 2024 April 2024
Slide 49: Analgesics
Category Size: SOM: Analgesics 2.4 Bn USD 7.6% Tafirol (Arg) #1 OTC brand Alliviax (Mx) #3 Analgesics brand XRay (Col) #3 Analgesics brand KEY HIGHLIGHTS: • Strong growth across the board • XRay +11.8% • Bioelectro +34.1% • Alliviax +3.3% +24% CAGR +14% (2018-2023) +13% Q1 2024 2018 2019 2020 2021 2
Slide 50: XRay (Col.) #3 Analgesic Brand
XRay (Col.) #3 Analgesic Brand SOM Evolution 10.2% 9.5% 7.5% 6.2% 3.6% 2.4% 2019 2020 2021 2022 2023 2024 April 2024
Slide 51: Genomma Lab Internacional
Genomma Lab Internacional April 2024 53
Slide 52: Cough & Cold
Category Size: SOM: Cough & Cold 2.1 Bn USD 4.8% Tukol #2 cough segment XL3 (Mx) #2 flu segment Next Global C&C Brand KEY HIGHLIGHTS: • Successful execution of winter strategy in Mexico • 81.5% growth in Next and 42.9% growth in XL3 • Milder winter in the US offsetting results +19% Tukol SOM CAGR +1
Slide 53: Gastro
Category Size: SOM: Gastro 1.7 Bn USD 3.4% Nikzon hemorroid leader in Latam QG5 #3 in pain & bloating segment KEY HIGHLIGHTS: • Strong growth across the board driven by new image • Nikzon +30.3% • QG5 20.9% • Genoprazol +23.4% CAGR +6% (2018-2023) +12% +27% Q1 2024 2018 2019 2020 2021 2022 2023 2024
Slide 54: Derma OTC
Category Size: SOM: Derma OTC 0.3 Bn USD 25.2% Silka + Unesia #1 (Latam) footcare OTC Lomecan #1 (Arg) and #2 (Mx) KEY HIGHLIGHTS: • Category relaunch in Mexico with new packaging design • Renewed TV campaign + robust in-store execution CAGR +0.2% (2018-2023) +5% +7% Q1 2024 2018 2019 2020 2021 2022
Slide 55: Infant Nutrition
Category Size: SOM: 1.8 Bn USD 1.8% TO FEED, TO CARE, TO MANAGE A range of superior science-based formulas to manage different baby needs and improve their quality of life…and that of their families! +44% CAGR +76% (2019-2023) SOM Total 1.8% Cow milk Allergy 26.6% Constipation 42.4% +50% Premium 2.2
Slide 56: Skin Care
Category Size: SOM: Skin Care 2.7 Bn USD 5.7% Genomma Lab #1 Category KEY HIGHLIGHTS: • +8.2% growth in Teatrical • Continued challenges in Cicatricure and Asepxia CAGR -6% (2018-2023) -3% -12% Q1 2024 2018 2019 2020 2021 2022 2023 2024 April 2024
Slide 57: Genomma Lab Internacional
Genomma Lab Internacional April 2024 59
Slide 58: Gross Annual Productivity
Gross Annual Productivity MXN 1.8 Bn 1600 1200 MXN 711 MM 40% of progress 800 400 0 2022 2023 2024 2025 2026 2027 April 2024
Slide 59: Productivity Examples: Go-to-Market
Productivity Examples GO-TO-MARKET MXN 207 MM IN 2023 Effective Price & Promotions
Slide 60: Productivity Examples: Redesign
Productivity Examples REDESIGN KEY INITIATIVES: • CAPS: New supplier development, cap redesign based on preform specs, improving line production efficiencies and cost reduction • SLEEVES: Volume leverage and cost reduction based on cost structure • PREFORM: Re-negotiation based on cost structure and
Slide 61: Productivity Examples
Productivity Examples MXN 93 MM SAVINGS Implemented productivity actions in Vanart • Packaging reengineering • Formula reengineering • Vertical integration of the bottle production process • Packaging & Raw Materials re-negotiations April 2024
Slide 62: Productivity Examples: New Suerox Line
Productivity Examples NEW SUEROX LINE
Slide 63: Logistic Discount - SLOG
J LOGISTIC DISCOUNT - SLOG Minimum order policy & centralized delivery =
Slide 64: Productivity Examples: Carton Folding Standardization
Productivity Examples CARTON FOLDING STANDARIZATION PROJECT From 23 supplier to 2 suppliers + = MXN 25 MM From 72 SKUs to 12 SKUs April 2024
Slide 65: Productivity Examples: Label Cost Optimization
Productivity Examples LABEL COST OPTIMIZATION PROJECT From 16 supplier to 2 supplier TOTAL SAVINGS MXN 22MM April 2024
Slide 66: Productivity Examples
Productivity Examples MXN 12MM SAVINGS April 2024
Slide 67: Productivity Examples: International Logistics Bidding
Productivity Examples International Logistics Bidding: MXN 11MM Including Freight & Forwarding SAVINGS 9 Different participants 3 Forwarders Selected 10 Ocean Routes quoted April 2024
Slide 68: Productivity Examples: Aluminum Foil Optimization
Productivity Examples Aluminum Foil Optimization: MXN 10MM Ink reduction and standardization SAVINGS Bidding process executed April 2024
Slide 69: Content
1 Who We Are: Our Footprint 2 4-year Profit & Growth Strategy Content 3 Unleashing Shareholder Value 4 Financial Review April 2024 71
Slide 70: Financial Highlights
4 Financial Highlights April 2024 72
Slide 71: Q1 2024 Overall Results
Q1 2024 OVERALL RESULTS LIKE-FOR-LIKE SALES 9.7% NET SALES (Ex Arg) 5.8% NET SALES 0.5% EBITDA 22.3% +153bps NET INCOME 372.1 +3.9% EPS 0.36 +6.8% CCC 103 d -3 d FCF (LTM) 1,780 MM % OF SALES GROWING SHARE 45% % OF SALES GROWING ABOVE INFLATION 78% Below target In-line with target Exceeded target Ap
Slide 72: EBITDA Margin Evolution
EBITDA Margin Evolution Quarter Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 EBITDA MARGIN 20.8% 21.1% 21.3% 20.8% 22.3% April 2024
Slide 73: Q1 2024 Overall Results by Category
Q1 2024 OVERALL RESULTS CORE CATEGORIES % GROWTH % GROWTH REPORTED L4L SKIN CARE (26.9)% (12.0)% COUGH & COLD 4.9% 13.6% ISOTONIC BEVERAGES 14.3% 14.4% ANALGESICS (7.9)% 13.0% HAIR CARE (8.8)% (0.7)% DERMA OTC (5.9)% 6.8% GASTRO 19.7% 26.5% INFANT NUTRITION 50.2% 50.2% RAZORS & BLADES 2.9% 13.2% TOT
Slide 74: Mexico Q1 2024
Mexico Q1 2024 • Net Revenues + 15 % • EBITDA margin 22.8% +460 bps April 2024
Slide 75: Exchange Rate: MXN / USD
Exchange Rate: MXN / USD Q1-23: Average $18.66 $20.0 Q1-23 vs Q1-24: (9.0)% $19.0 $18.0 $17.0 Q1-24: $16.98 $16.0 $15.0 1Q 23 2Q 23 3Q 23 4Q 23 1Q 24 Average exchange rate for each period. Source: Banxico. April 2024
Slide 76: U.S.A. Q1 2024
U.S.A. Q1 2024 • Net Revenues: 0.5% in USD (10.7)% in MXN • EBITDA margin: 14.1% +500 bps April 2024
Slide 77: LatAm FX Depreciation
LatAm FX Depreciation Local Currency vs MXN* (77.6)% PYG (9.1%) CLP (22.0%) USD (9.0%) U (8.2%) PEN (7.5%) BRL (4.5%) April 2024
Slide 78: LATAM w/o Argentina Q1 2024
LATAM w/o Argentina Q1 2024 • Net Revenues Ps 1.25 billion • EBITDA Ps. 420.9 million • EBITDA margin 23.7% April 2024
Slide 79: Cash Conversion Cycle
Cash Conversion Cycle Q1 2024 Q1 2023 Δ Days of Accounts Receivable (DSO) Q1 2023 Q4 2023 Q1 2024 Receivable days 100 94 6 Inventory days 113 124 -11 Mexico 123 89 99 Payable days 110 113 -3 Lat Am 77 101 95 U.S. 51 53 60 Cash Conversion Cycle 103 106 -3 Consolidated 94 83 94 April 2024
Slide 80: Short Term Debt in Capital Markets
Short Term Debt in Capital Markets: Monto de $125 $25 $115 $185 Emisión millones Millones Millones millones Calificación “F1+(mex)” por Fitch Ratings y “HR+1” por HR Ratings Clave LAB 00224 LAB 00324 LAB 00424 LAB 00524 Plazo 168 días 364 días 77 días 168 días Sobretasa TIIE 28 0.12% 0.15% 0.12% 0.1
Slide 81: Financial Leverage
Financial Leverage (Millions of MXN) • Net Debt / EBITDA of 1.4x • Long-term debt 66.1% of total April 2024
Slide 82: LABB Share Buyback
LABB Share buyback Million shares 35 30.1 30 25 28 million shares 20 million were cancelled on April, shares 20 2023 to be cancelled pending approval at 15 the upcoming AGSM 10 6.5 5 4.5 2.5 2.8 2.9 0 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 April 2024
Slide 83: Cash Dividend Payments
Cash Dividend Payments • 200 million on March 25th th 7 Dividend Payment • The Company aims to continue paying dividends on a Quarterly basis April 2024
Slide 84: Annexes
Genomma Lab.° Internacional April 2024 86
Slide 85: Economies of Scale and Scope Driving Higher Gross Margins
Economies Of Scale And Scope Driving Higher Gross Margins Opportunity Outsourcing Producing areas Direct control in all Buying finished Raw Materials products COGS and components Fragmented raw Packaging material Economies of scale procurement Low scale, labor State-of-the-art fully Labor Cost inten
Slide 86: Economies of Scale and Scope Driving Higher Gross Margins
Economies Of Scale And Scope Driving Higher Gross Margins Opportunity Outsourcing Producing areas Higher COGS due to Eliminate co- Suppliers co-packers profit packers profit margin margin Suppliers scattered Integration of throughout the suppliers to country industrial park Logistics Leverage freigh
Slide 87: OTC Market Share by Country
OTC Market Share By Country Top Two Countries Growth Potential Leadership CAM (1) ECUADOR position position position 4th. 4th. 3rd. MEXICO PLACE CHILE > 70% share PERÚ position in the Region position 5th. 6th. position ARGENTINA 1st. COLOMBIA PLACE position 7th. > 30% share Source: IMS Health. Ranki
Slide 88: Profitability Through COGS Reduction
Profitability Through COGs Reduction 38 39 Acquired in 2012 32 34 from Sidus Market 25.4 Share in 24.2 23. 21 21. units (%) 20.3 Competitor ‘13 ‘14 ‘15 ‘16 ‘17 ’18 51 33.91 25.39 Net Sales 20.69 in USD 9.87 13.67 million Portfolio of products ‘13 ‘14 ‘15 ‘16 ’17 ’18 Source: Cid Latina – N02B + M01A.
Slide 89: Industrial Complex - EDGE Certification
Industrial Complex– EDGE Certification GENOMMA LAB ACHIEVES WORLD BANK / IFC’s EDGE CERTIFICATION EDGE ISA GREEN BUILDINGSTANDARD AND A GLOBAL CERTIFICATION SYSTEM FIRST PHARMACEUTICAL PLANT IN THE WESTERN HEMISPHERE TO MEET STANDARDS April 2024 91
Slide 90: Industrial Complex - EDGE Certification
Industrial Complex– EDGE Certification Plant design enables: PERSONAL CARE PLANT SAVINGS: - 31% in energy - 52% in water - 41% in embodied energy - 87 tons of CO2 PHARMA PLANT SAVINGS: - 45% in energy - 37% in water - 42% in embodied energy - 33 tons of CO2 DISTRIBUTION CENTER SAVINGS: - 26% in ener
Slide 91: OTC Manufacturing Plant Permits Update
OTC Manufacturing Plant Permits Update Granted INTERNATIONAL GMPs Pending Approval Not submitted MEXICO GMP SANITARY LICENSE Solid Semi-Solid Oral Liquid Topical Liquid Coating April 2024
Slide 92: IFC and Genomma Lab Multi-currency Long-term Loan
IFC and Genomma Lab Multi-currency Long-term Loan • IFC’s first multi-currency investment in the pharmaceutical industry anywhere in the world US$60 million loan: • CHILEAN PESOS • PERUVIAN SOLES • US DOLLARS • MEXICAN PESOS • COLOMBIAN PESOS April 2024 94
Slide 93: Enhancing our Megabrand Potential
Enhancing our Megabrand potential Example of Analgesics category April 2024 95
Slide 94: M&A Transactions in Consumer Health Categories
M&A Transactions in Consumer Health Categories CHC MAJOR ACQUISITION MULTIPLES EV / Sales Multiple 9.0 BMS LatAm to Reckitt Paras to Reckitt 8.2 Merck CC to Bayer Adams RT to 6.9 Insight to Prestige 6.5 Swisse to Mead Matrixx to GSK brands Reckitt Church & to Pharma Biostime Johnson Dwight Fertin SG
Slide 95: OTC Pharma EV / LTM EBITDA Transaction Multiples
OTC Pharma EV / LTM EBITDA Transaction Multiples Average 16.3 x Source: Credit Suisse April 2024 97
Slide 96: Dynamism in M&A Pharma
Dynamism in M&A Pharma April 2024 98
Slide 97: Personal Care and Skin Care Price/Sales Transaction Multiples
PERSONAL CARE Price/Sales Transaction Multiples Source: Credit Suisse SKIN CARE Price/Sales Transaction Multiples Source: Credit Suisse April 2024 99
Slide 98: Comparables in the Beverage Industry
Comparables in the Beverage Industry BEVERAGES EV/Sales Transaction Multiple April 2024 100
Slide 99: M&A Dynamism in the Beverage Industry
M&A Dynamism in the Beverage Industry Focused on high growth / high margin brands April 2024 101
Slide 100: Genomma Lab Internacional
Genomma Lab Internacional April 2024 102
Genomma Lab Internacional — Investor Presentation (May 2024) on 6ix